Medifast, Inc. (MED) SEC Filings & Earnings Calls

GLP-1 medication adoption continues to pressure client acquisition and coach network.

“Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.” · word for word

Active earning coach count expected to continue declining in 2026.

“While the company continues its transformation to focus on metabolic health, it expects the number of active earning coaches to continue to decline in 2026.” · word for word

GLP-1 Competitive Disruption

“Medical weight loss solutions, such as GLP-1 medications, have become an increasingly key component of the overall health and wellness ecosystem, and the recent surging acceptance and popularity of these weight loss medications serve as another major competitor, as these products have prompted a huge change in the way that consumers think about weight loss a” · word for word

Coach Network Attrition

“The decline in revenue for the three months ended June 30, 2026 was primarily driven by a decrease in the number of active earning coaches to 11,700 for the three months ended June 30, 2026 from 22,800 for the three months ended June 30, 2025.” · word for word

Tariff/Inflation Cost Pressure

“Increases in commodity prices, food costs, or tariffs could affect the global and U.S. economies and could also adversely impact our business, financial condition, or results of operations.” · word for word

Key legal officer departure may cause temporary disruption in legal oversight.

“Resignation of CLO; company states no disagreement.”

CEO transition may cause strategic uncertainty, but planned succession mitigates risk.

“Chard's planned transition announced earlier; Johnson internal promotion.”

GLP-1 Competitive Disruption

“The decrease in active earning coaches for the quarter, which has been trending downward year-over-year since the first quarter of 2023, was driven by continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.” · word for word

Coach Network Attrition

“The decline in revenue for the three months ended March 31, 2026 was primarily driven by a decrease in the number of active earning coaches to 14,000 as of March 31, 2026 from 25,400 as of March 31, 2025.” · word for word

Revenue Decline Trajectory

“Revenue decreased $39.7 million, or 34.3%, to $76.0 million for the three months ended March 31, 2026 from $115.7 million for the three months ended March 31, 2025.” · word for word

GLP-1 medication adoption continues to disrupt Medifast's weight loss program demand, driving coach and revenue decline.

“Continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.” · word for word

Active earning coach count expected to continue declining in 2026, indicating ongoing structural contraction.

“Company expects the number of active earning coaches to continue to decline in 2026.”

GLP-1 Competitive Threat

“the changing competitive landscape, including the impact of GLP-1 medications” · word for word

Revenue Decline

“ongoing revenue decline” · word for word

Strategic Transformation Execution Risk

“transitioning from transformation to execution” · word for word

Key Person / Leadership Transition Risk

“a leadership transition announced in January 2026” · word for word

GLP-1 Competition Risk

“The growing popularity of weight loss solutions, such as a drug therapy or GLP-1 medications, which may be perceived to be safe, effective and 'easier' than a portion-controlled meal plan has affected the marketplace and could negatively impact our results of operations.” · word for word

Coach Network Attrition Risk

“The number of active earning coaches has been trending downward year-over-year since the first quarter of 2023.” · word for word

Continued erosion of coach base due to GLP-1 competition and broader challenges.

“Active earning coaches decreased 40.6% to 16,100 compared to 27,100 for Q4 2024.”

Non-cash valuation allowance on deferred tax assets indicates uncertainty about future profitability.

“Net loss includes $12.1M non-cash valuation allowance on deferred tax assets.”

Operating losses and negative operating leverage as revenue declines.

“Loss from operations was $7.8 million compared to income from operations of $0.7 million.” · word for word

GLP-1 medication adoption continues to erode client acquisition and coach network, with no sign of stabilization.

“continued challenges with client acquisition due to the growing acceptance of GLP-1 medications for weight loss.” · word for word

Gross margin pressure from fixed cost deleverage and product reformulation reserve may persist as revenue declines.

“450 basis points of loss of leverage on fixed costs and 180 basis points of reserve for the reformulation of the Essential product line.” · word for word

Q4 guidance implies further revenue decline and widening losses, suggesting no near-term recovery.

“fourth quarter 2025 revenue to be in the range of $65 million to $80 million and fourth quarter 2025 diluted loss per share to be in the range of $0.70 to $1.25.” · word for word

GLP-1 competitive disruption

“The decrease in productivity per active earning OPTA VIA coach for the three months ended September 30, 2025 was driven by continued pressure with client acquisition reflecting broader challenges in the operating environment, including rapid adoption of GLP-1 medications for weight loss.” · word for word

Coach attrition spiral

“The number of active earning OPTA VIA coaches has been trending downward year-over-year since the first quarter of 2023.” · word for word

Fixed cost deleverage

“As a percentage of revenue, gross profit decreased 590 basis points to 69.5% for the three months ended September 30, 2025 from 75.4% for the corresponding period in 2024 primarily due to 450 basis points attributable to loss of leverage on fixed costs.” · word for word